SLX-2101 clinical trials
Also written SLx-2101.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses SLX-2101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SLx-2101
- 3
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Retension Pharmaceuticals. Inc. (2) · Response Pharmaceuticals (1)
Studies
Open first, then newest update. How each study uses SLX-2101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With HypertensionCompletedPhase 2Retension Pharmaceuticals. Inc.NCT00562614Written as SLx-2101
- Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With HypertensionCompletedPhase 2Retension Pharmaceuticals. Inc.NCT00562549Written as SLx-2101
- Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's DiseaseCompletedPhase 2Response PharmaceuticalsNCT00528242Written as SLx-2101